Clene Inc. to Showcase Neurodegenerative Disease Treatments at Canaccord 45th Annual Growth Conference

Clene Inc. (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, is set to present at the Canaccord 45th Annual Growth Conference, showcasing its groundbreaking work in developing treatments for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). This presentation marks a significant opportunity for Clene to engage with investors and highlight the potential of its investigational therapy, CNM-Au8(R), which aims to improve mitochondrial health and neuronal function.

The company's participation in the conference underscores the importance of its research in addressing some of the most challenging neurodegenerative diseases. CNM-Au8(R), Clene's flagship product, represents a novel approach to treatment by targeting mitochondrial function and the NAD pathway, offering hope for patients with limited therapeutic options. For more details on Clene's innovative research and development efforts, visit https://ibn.fm/joSXx.

Clene's commitment to advancing treatments for neurodegenerative diseases is further evidenced by its active engagement in one-on-one investor meetings during the conference. These interactions are crucial for fostering partnerships and securing the support needed to bring CNM-Au8(R) and other therapies to market. The company's presence at such a prestigious event highlights the growing interest and investment in biopharmaceutical innovations aimed at improving patient outcomes in neurodegenerative conditions.

For investors and stakeholders interested in the latest developments from Clene Inc., additional information is available in the company's newsroom at https://ibn.fm/CLNN. Clene's participation in the Canaccord 45th Annual Growth Conference is a testament to the company's leadership in the biopharmaceutical industry and its dedication to addressing unmet medical needs in neurodegenerative diseases.